Merck’s Cancidas Adds Indication For Febrile Neutropenia Fungal Infections
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental approval was based on a 1,111-patient clinical trial that demonstrated Cancidas to be as effective as Gilead/Fujisawa’s AmBisome. Merck is using the study to promote caspofungin’s safety profile compared to AmBisome.